Literature DB >> 17630604

New adolescent vaccination recommendations and how to make them "stick".

Amy B Middleman1.   

Abstract

PURPOSE OF REVIEW: Multiple vaccination recommendations have recently targeted the adolescent age group. It is important for providers to be aware of all new recommendations, the rationale for the recommendations, and how to best implement recommendations for this age group. RECENT
FINDINGS: The 11-12-year-old immunization platform now includes vaccination against tetanus, diphtheria, pertussis (tetanus, diphtheria and acellular pertussis or Tdap vaccine), meningococcal disease (conjugate meningococcal vaccine), human papillomavirus (for females), and a second varicella vaccination for those who have received one vaccination and have not had disease. Any missing vaccinations should be updated at this time. Many strategies exist to improve adherence to adolescent recommendations; the school mandate is an important yet controversial strategy that is being hotly debated in the literature.
SUMMARY: There are many exciting, new vaccines for adolescents. It is important to improve vaccination coverage within the adolescent age group. Immunization against disease has previously been viewed as a primarily childhood issue, yet with ever-evolving technology and the need to vaccinate against diseases affecting all ages, vaccination strategies for adolescents need to be reviewed and improved. Mandates, when initiated with care, are one of the most effective implementation strategies for adolescents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630604     DOI: 10.1097/MOP.0b013e3281e72cd2

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  2 in total

1.  Human papillomavirus vaccine uptake among 9- to 17-year-old girls: National Health Interview Survey, 2008.

Authors:  Charlene A Wong; Zahava Berkowitz; Christina G Dorell; Rebecca Anhang Price; Jennifer Lee; Mona Saraiya
Journal:  Cancer       Date:  2011-06-20       Impact factor: 6.860

2.  Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.

Authors:  Roberto Gasparini; Michele Conversano; Gianni Bona; Giovanni Gabutti; Alessandra Anemona; Peter M Dull; Francesca Ceddia
Journal:  Clin Vaccine Immunol       Date:  2010-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.